| Trial ID: | L5315 |
| Source ID: | NCT02558270
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
Effects of SGLT-2 Inhibition on Hepatic Glucose and Energy Metabolism
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes|Metabolically Healthy Controls
|
| Interventions: |
DRUG: Dapagliflozin|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change in endogenous glucose production, 420 minutes | Secondary: Change in hepatic gluconeogenesis, 420 minutes|Change in hepatic lipid content, 420 minutes|Change in hepatic glycogen content, 420 minutes|Changes in hepatic ATP concentrations, 420 minutes|Changes in hormones involved in hypoglycemia counter regulation, 420 minutes
|
| Sponsor/Collaborators: |
Sponsor: Medical University of Vienna
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
20
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2016-06
|
| Completion Date: |
2018-06
|
| Results First Posted: |
|
| Last Update Posted: |
2016-09-27
|
| Locations: |
Medical University Of Vienna, Department of Internal Medicine III, Vienna, 1090, Austria
|
| URL: |
https://clinicaltrials.gov/show/NCT02558270
|
